A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced ...
All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback